Setting the body’s ‘serial killers’ loose on cancer

 Dr. Steve Rosenberg’s work is highlighted in the New York Times series, “Cell Wars”. After a long, intense pursuit, researchers are close to bringing to market a daring new treatment: cell therapy that turbocharges the immune system to fight cancer. More

8-year-old girl in remission after immunotherapy clinical trial

8-year-old Ava Christianson’s acute lymphoblastic leukemia has relapsed five times. She is currently in remission after participating in a CAR T-cell therapy clinical trial under the care of physician-scientist Dr. Terry Fry of the Pediatric Oncology Branch. More on this Washington Post article


Liver disease stage determines whether the immune response stifles or stimulates tumor growth

Researchers at the Center for Cancer Research and colleagues from three cancer research centers in Germany have discovered a mechanism whereby precancerous liver cells, found in individuals with chronic liver disease, can prevent neighboring cells from becoming cancerous but can also speed the growth of cells that have already become cancerous.  More


Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

Thomas Uldrick, senior clinician in the HIV and AIDS Malignancy Branch, has launched a new phase 1 trial evaluating the immunotherapy drug Keytruda, which is designed to target cancer cells in HIV-positive cancer patients. Cancer Today reported that many HIV-positive patients with cancer do not get proper treatment for their cancers, and Uldrick hopes the drug will kill both cancer cells and HIV cells. More

Steven Pavletic discusses new strategies to target GVHD

Steven Pavletic, senior clinician in the Experimental Transplantation and Immunology Branch, discussed new strategies for treating graft-versus-host disease with OncLive. He says these new strategies are the result of improved understanding of the disease’s pathophysiology, and the new therapies could lead to less toxic and more effective therapies. More

High levels of potassium inside tumors suppress immune activity

Nicholas P. Restifo, a senior investigator in CCR’s Surgery Branch and his team have discovered that an abundance of potassium inside tumors dampens immune responses, helping the tumors evade the body’s defenses. In animal experiments, genetically equipping immune cells rid themselves of potassium made them more effective at fighting cancer. The finding, published September 14, 2016, in the journal Nature, suggests a tactic for improving the effectiveness of cancer immunotherapies. More  


Tumor DNA in blood may signal response to T-cell transfer immunotherapy


CCR researcher finds oxygen can impair cancer immunotherapy in mice


New immunotherapy gives tumor-fighting immune cells the chance to attack


“Scientific pioneer”: Steven Rosenberg honored with Novartis Prize in Immunology